Integrated study on pharmacokinetics and pharmacodynamics for efficient drug discovery and on the optimum drug therapy
Basic and clinical analysis of drug-metabolizing enzyme and transporters influencing pharmacokinetics and pharmaco-dynamics
Basic research on the toxicity mechanism of drugs, xenobiotics and their active metabolites
The elucidation of relationship between pharmacokinetics (PK) and pharmacodynamics (PD) of drugs is critical not only for the discovery of novel drugs but also for their optimum uses in clinical settings. The effects of clinically used drugs are influenced by drug-metabolizing enzymes and drug-transporters. Therefore, one of our major research projects is to push an integrated analysis of PK and PD for investigational drugs by characterizing in vivo drug-metabolizing enzymes and drug-transporters under physiological and pathological conditions. We are also conducting the research of mechanism(s) for the decrease in levels of serum thyroid hormones by xenobiotics and their active metabolites, and the species difference and extrapolation to human in these compounds-induced alteration of the hormone levels.
In addition to these projects, we have also focused on simultaneous determination of polybrominated diphenyl ethers (PBDEs), hydroxylated (OH-) and methoxylated (MeO-) PBDEs found in marine sponge by atmosphere pressure chemical ionization tandem mass spectrometry (APCI-LC/MS/MS), and immunotargeting of liposome to tumor and endothelial cell expressed membrane type-1 matrix metalloproteinase (MT1-MMP).
